Evaluation of the Effects of I-PRF and C-PRF on Gingival Phenotype

NCT06964529 | Completed

• 1 other identifier: 2024/74 - PRF
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial aims to evaluate the effects of injectable platelet-rich fibrin (I-PRF) and concentrated platelet-rich fibrin (C-PRF) on gingival phenotype in patients undergoing mucogingival surgery with the VISTA technique. Changes in gingival thickness and width of keratinized gingiva will be assessed using both manual and digital methods.

Conditions

Thin Gingiva; Thin Gingival Biotype

Keywords

C-PRF; I-PRF; VISTA Technique

Outcome Measures

Primary Outcomes (1)

• Change in gingival thickness

  Gingival thickness will be measured manually (using a spreader) to assess the effect of I-PRF and C-PRF over time.

  Baseline, 1 month, 3 months and 6 months.

Secondary Outcomes (1)

• Change in width of keratinized gingiva

  Baseline, 1 month, 3 months and 6 months

Study Arms (2)

C-PRF Group

EXPERIMENTAL

Concentrated platelet-rich fibrin was prepared using horizontal centrifugation and injected at 4 time points (once during the VISTA procedure, and 3 additional times at 10-day intervals).

Biological: Concentrated PRF

I-PRF Group

EXPERIMENTAL

Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions).

Biological: Injectable PRF

Interventions

Concentrated PRF BIOLOGICAL

Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).

Also known as: C-PRF

C-PRF Group

Injectable PRF BIOLOGICAL

Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).

Also known as: I-PRF

I-PRF Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Systemically healthy individuals (ASA I) Age between 18 and 45 years Non-smokers Gingival thickness ≤ 0.8 mm in the mandibular anterior region No restorations, missing teeth, or supernumerary teeth in the mandibular anterior region Full-mouth plaque index (PI) \< 15% Full-mouth bleeding on probing (BOP) \< 15%

You may not qualify if:

• Presence of systemic disease or coagulation disorders Use of antibiotics or anti-inflammatory drugs within the last 3 months Smoking History of bruxism Pregnancy or lactation Ongoing orthodontic treatment Use of medications affecting gingival phenotype (e.g., calcium channel blockers, anticonvulsants) Presence of infection, lesion, or trauma at the surgical site History of periodontal surgery in the relevant area

Sponsors & Collaborators

• Inonu University: lead

Study Sites (1)

Inonu University Faculty of Dentistry

Malatya, Turkey (Türkiye)

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Assistant

Model Details: Two-arm parallel design comparing the effects of I-PRF and C-PRF on gingival phenotype using VISTA technique.

Study Record Dates

• First Submitted: May 1, 2025
• First Posted: May 9, 2025
• Study Start: February 11, 2025
• Primary Completion: July 15, 2025
• Study Completion: August 10, 2025
• Last Updated: March 27, 2026

Record last verified: 2026-03

Locations

TU (1)